Armata Pharmaceuticals (ARMP) closed at $3.00 on November 5, 2026, down 4.5% from the previous close, on volume of 45,261 shares (30-day average 94,815).
Data as of November 5, 2026.
5-Nov-2026
PRNewswire (Wed, 7-Oct 7:00 AM ET)
PRNewswire (Wed, 23-Sep 7:00 AM ET)
PRNewswire (Mon, 21-Sep 7:00 AM ET)
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
PRNewswire (Mon, 14-Sep 7:01 AM ET)
PRNewswire (Thu, 10-Sep 7:00 AM ET)
PRNewswire (Thu, 3-Sep 7:00 AM ET)
PRNewswire (Wed, 12-Aug 4:05 PM ET)
Market Chameleon (Tue, 13-Jan 2:51 AM ET)
Market Chameleon (Thu, 23-Oct 3:07 AM ET)
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
Armata Pharmaceuticals trades on the AMEX stock market under the symbol ARMP.
As of November 5, 2026, ARMP stock price declined to $3.00 with 45,261 million shares trading.
ARMP has a beta of 0.24, meaning it tends to be less sensitive to market movements. ARMP has a correlation of 0.00 to the broad based SPY ETF.
ARMP has a market cap of $111.55 million. This is considered a Micro Cap stock.
Last quarter Armata Pharmaceuticals reported $3 million in Revenue and -$.27 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.18.
In the last 3 years, ARMP traded as high as $16.34 and as low as $.90.
The top ETF exchange traded funds that ARMP belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
ARMP has underperformed the market in the last year with a price return of -47.0% while the SPY ETF gained +9.7%. ARMP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -36.2% and -13.0%, respectively, while the SPY returned -4.7% and -5.2%, respectively.
ARMP support price is $2.87 and resistance is $3.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARMP shares will trade within this expected range on the day.
